MedPath

Dienogest a tablet used in the treatment of ovarian cyst

Phase 2
Conditions
Health Condition 1: N801- Endometriosis of ovary
Registration Number
CTRI/2020/04/024793
Lead Sponsor
KMC Manipal
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Ultrasonographic diagnosis of ovarian endometrioma with mean diameter of 40mm or less

2.Atleast one symptoms like dysmenorrhea,chronic pelvic pain, dyspareuria should be present

Exclusion Criteria

1.Patients planned for surgical management

2. any harmonal therapy undertaken within three months before enrollment

3. patients with suspected malignancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the efficacy of Tab Dienogest 2mg in reducing the size of endometriosis and related symptomsTimepoint: 6 Months
Secondary Outcome Measures
NameTimeMethod
Improvement in quality of lifeTimepoint: 6 months
© Copyright 2025. All Rights Reserved by MedPath